Drugs analysed were prednisolone, vincristine, daunorubicin, asparaginase, cytarabine, cyclophosphamide, 6-thioguanine (the active metabolite of 6-mercaptopurine) and mitoxantrone, used in newly diagnosed ALL9; bortezomib, used in relapsed ALL16; and panobinostat, venetoclax, selinexor, three novel agents with reported activity in ALL, available to us at that time. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.